(2S)-2-((3S)-3-{[(benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoic acid | 217969-71-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-((3S)-3-{[(benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoic acid
• 英文别名: (2S)-2-[(3S)-2-oxo-3-(phenylmethoxycarbonylamino)pyrrolidin-1-yl]propanoic acid
• CAS: 217969-71-6
• 化学式: C₁₅H₁₈N₂O₅
• 分子量: 306.318
• InChiKey: UIOKCSZHZMGVMR-JQWIXIFHSA-N

物化性质

• 沸点：
  576.7±50.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S)-2-((3S)-3-{[(benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoic acid 在 palladium on activated charcoal 氢气 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide
  参考文献：
  名称：

  Factor Xa Inhibitors:  S1 Binding Interactions of a Series of N-{(3S)-1-[(1S)-1-Methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides

  摘要：

  Factor Xa inhibitory activities for a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides with different P1 groups are described. These data provide insight into binding interactions within the S1 primary specificity pocket; rationales are presented for the derived SAR on the basis of electronic interactions through crystal structures of fXa-ligand complexes and molecular modeling studies. A good correlation between in vitro anticoagulant activities with lipophilicity and the extent of human serum albumin binding is observed within this series of potent fXa inhibitors. Pharmacokinetic profiles in rat and dog, together with selectivity over other trypsin-like serine proteases, identified 1f as a candidate for further evaluation.

  DOI：

  10.1021/jm060870c
• 作为产物：
  描述：

  N-Cbz-L-蛋氨酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 、 碘甲烷 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 113.0h， 生成 (2S)-2-((3S)-3-{[(benzyloxy)carbonyl]amino}-2-oxopyrrolidin-1-yl)propanoic acid
  参考文献：
  名称：

  Factor Xa Inhibitors:  S1 Binding Interactions of a Series of N-{(3S)-1-[(1S)-1-Methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides

  摘要：

  Factor Xa inhibitory activities for a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides with different P1 groups are described. These data provide insight into binding interactions within the S1 primary specificity pocket; rationales are presented for the derived SAR on the basis of electronic interactions through crystal structures of fXa-ligand complexes and molecular modeling studies. A good correlation between in vitro anticoagulant activities with lipophilicity and the extent of human serum albumin binding is observed within this series of potent fXa inhibitors. Pharmacokinetic profiles in rat and dog, together with selectivity over other trypsin-like serine proteases, identified 1f as a candidate for further evaluation.

  DOI：

  10.1021/jm060870c

文献信息

• [EN] PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA<br/>[FR] DERIVES DE PYRROLYDIN-2-ONE UTILISES COMME INHIBITEURS DE LA THROMBINE ET DU FACTEUR XA
  申请人：GLAXO GROUP LTD

  公开号：WO2004052851A1

  公开（公告）日：2004-06-24

  The invention relates to compounds of formula (I), wherein : R1 represents hydrogen, C1-4 alkyl, -CH2CO2H, -CH2CO2C1-2alkyl, or -CH2CONR7R8; R2 and R3 independently represent hydrogen, -C1-6alkyl, -C1-3alkylCN, -C1-3alkylCO2H, -C1-4alkylOC1-4alkyl, -C1-4alkylS(O)nC1-4alkyl, -C1-4alkylNR10R11, -C1-3alkylNCO2C1-4alkyl, -C1-3alkylCONR7R8, -C1-3alkylCO2C0-2alkylR9, -C1-3alkylCOC0-2alkylR9, -C1-3alkylCON(R8) C0-2 alkylR9, -C1-3alkylNCO2C0-2alkylR9, -C1-3alkylNCOC0-2alkylR9 or -C0-2alkylR9, with the proviso that one of R2 and R3 is hydrogen and the other is a substituent other than hydrogen; n is an integer between 0 and 2; R4 and R5 together with the nitrogen atom to which they are attached form a morpholino ring; R6 represents a group selected from formula (II) wherein T1 and T2 independently represent CH2, NH, S or O with the proviso that when one of T1 or T2 represents NH, S or O the other represents CH2; M represents CH3, -OH or PO; V represents CH or N; W represents H, CH3, Cl or F; X represents C1, Br, F or -CH3; Y represents CH3 or CF3; Z represents -CH3 or F; R7 and R8 are independently hydrogen, C1-4alkyl or together with the N atom to which they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additional heteroatom selected from O, N or S; R10 and R11 independently represent C1-4alkyl or together with the N atom towhich they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additionalheteroatom selected from O, N or S; R9 represents phenyl or a 5- or 6- membered aromatic or non-aromatic heterocyclic group, containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: C1-3alkyl or halogen; and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a thrombin inhibitor is indicated.

  该发明涉及式(I)的化合物，其中：R1代表氢，C1-4烷基，-CH2CO2H，-CH2CO2C1-2烷基，或-CH2CONR7R8；R2和R3独立地代表氢，-C1-6烷基，-C1-3烷基CN，-C1-3烷基CO2H，-C1-4烷基OC1-4烷基，-C1-4烷基S(O)nC1-4烷基，-C1-4烷基NR10R11，-C1-3烷基NCO2C1-4烷基，-C1-3烷基CONR7R8，-C1-3烷基CO2C0-2烷基R9，-C1-3烷基COC0-2烷基R9，-C1-3烷基CON(R8) C0-2烷基R9，-C1-3烷基NCO2C0-2烷基R9，-C1-3烷基NCOC0-2烷基R9或-C0-2烷基R9，但要求R2和R3中的一个为氢，另一个为非氢取代基；n是0到2之间的整数；R4和R5与它们连接的氮原子一起形成吗啡环；R6代表从式(II)中选择的基团，其中T1和T2独立地代表CH2，NH，S或O，但要求当T1或T2代表NH，S或O时，另一个代表CH2；M代表CH3，-OH或PO；V代表CH或N；W代表H，CH3，Cl或F；X代表C1，Br，F或-CH3；Y代表CH3或CF3；Z代表-CH3或F；R7和R8独立地代表氢，C1-4烷基，或者与它们连接的N原子一起形成一个5-或6-成员非芳香杂环，选择性地包含另一个从O，N或S中选择的杂原子；R10和R11独立地代表C1-4烷基，或者与它们连接的N原子一起形成一个5-或6-成员非芳香杂环，选择性地包含另一个从O，N或S中选择的杂原子；R9代表苯基或一个5-或6-成员芳香或非芳香杂环基团，其中至少含有一个从O，N或S中选择的杂原子，每个基团选择性地被0-2个从C1-3烷基或卤素中选择的基团取代；以及其药用可接受的衍生物，其制备方法，含有它们的药物组合物以及在医学中的使用，特别是在改善需要凝血酶抑制剂的临床状况中的使用。
• [EN] PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA<br/>[FR] DERIVES PYRROLIDINE-2-UN COMME INHIBITEURS DE FACTEUR XA
  申请人：GLAXO GROUP LTD

  公开号：WO2002100886A1

  公开（公告）日：2002-12-19

  The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  本发明涉及式(Ic)化合物、其制备过程、含有它们的药物组合物以及它们在医学上的应用，特别是在改善适用于因子Xa抑制剂的临床状况方面的应用。
• [EN] PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS<br/>[FR] DERIVES DE PYRROLIDINE SERVANT D'INHIBITEURS DU FACTEUR XA
  申请人：GLAXO GROUP LTD

  公开号：WO2002100830A1

  公开（公告）日：2002-12-19

  The invention relates to compounds of formula (I) which processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  本发明涉及式（I）的化合物，以及制备它们的方法，包含它们的制药组合物以及它们在医学上的使用，特别是在改善需要使用Factor Xa抑制剂的临床状况方面的使用。
• Pyrrolidine derivatives as factor xa inhibitors
  申请人：Chan Chuen

  公开号：US20050107379A1

  公开（公告）日：2005-05-19

  The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  本发明涉及公式（I）的化合物、其制备方法、包含它们的药物组合物以及它们在医学中的使用，特别是在改善需要使用Xa因子抑制剂的临床病情方面的使用。
• 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
  申请人：Borthwick David Alan

  公开号：US20050004119A1

  公开（公告）日：2005-01-06

  The invention relates to compounds of formula (I) pharmaceutical compositions containing the same as well as methods of treating patients suffering from a condition susceptible to amelioration by a Factor Xa inhibitor using the same.

  本发明涉及化合物(I)的配方、包含该化合物的药物组合物，以及使用该组合物治疗患有易于通过因子Xa抑制剂改善的疾病的患者的方法。